RekryteringTerapeutisk bekräftande (Fas III)Interventionell

Longitudinal study of clinical outcome measures in adult patients with Spinal Muscular Atrophy (SMA) treated with Risdiplam.

Q: Can I stop participating in the study if I change my mind?

Yes, you can choose to leave the study at any time, for any reason, without it affecting your medical care.

This important study is looking into how a medicine called Risdiplam, also known as Evrysdi, affects adults who have a condition called Spinal Muscular Atrophy (SMA) type 2 or 3. The main goal is to find out if this medicine helps improve how people feel and function in their daily lives over a period of two years. Researchers will also be checking the medicine's safety and if it causes any side effects. This type of study, called a Phase III trial, is a crucial step to confirm how well a new treatment works and ensures it's safe for wider use. It's designed to bring us closer to understanding the best ways to manage SMA.

Överblick

Status

Rekrytering

Fas

Terapeutisk bekräftande (Fas III)

Sponsor

UZ Leuven

Inskrivningsmål

Starta

28 Nov 2022

Spinal Muscular Atrophy (SMA)

Vad handlar denna studie om?

This study is about a medicine called Risdiplam, which you might know as Evrysdi. It’s for adults who have a condition called Spinal Muscular Atrophy (SMA), specifically types 2 or 3, or who have up to 4 copies of a gene called SMN2. SMA is a genetic condition that affects the nerves that control muscle movement.

The main aim of this research is to understand how Risdiplam affects the daily lives and physical abilities of these adult patients over a two-year period. Researchers will be looking at things like how strong muscles are, how well people can move, and other measures of their overall health and function. They'll compare these measures at the beginning of the study to how they are after 24 months of treatment.

Alongside checking how people's abilities change, the study will also carefully look at how safe Risdiplam is and if people can take it without too many problems. This includes checking for any side effects and looking at certain markers in the blood that can tell us about nerve health. This kind of study is crucial because it helps doctors and patients understand what to expect from treatments for SMA.

Viktiga punkter

The study examines Risdiplam (Evrysdi) for adults with SMA Type 2 or 3.
It aims to see if the medicine improves daily life and physical function over two years.
Safety and side effects of Risdiplam will also be carefully checked.
Participation requires regular clinic visits and taking the study medication.
Du kan sluta delta i studien när som helst.

Vem kan vara berättigad?

To be part of this study, you need to be an adult, 18 years old or older. There isn't an upper age limit, so people of all adult ages are welcome to be considered.

Both men and women can take part in this research. The study is specifically for adults who have been diagnosed with Spinal Muscular Atrophy (SMA) of type 2 or type 3. It also includes people who have a certain genetic make-up related to SMA, specifically those with up to 4 copies of the SMN2 gene.

Basically, if you're an adult living with SMA Type 2 or 3, or you meet the SMN2 gene copy criteria, you might be able to join. The research team will carefully check to make sure the study is a good fit for you and that it's safe for you to participate.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

Är du 18 år eller äldre?
Do you have a diagnosis of Spinal Muscular Atrophy (SMA) Type 2 or Type 3?
Do you have up to 4 copies of the SMN2 gene?
Are you able to commit to taking the medicine and attending regular check-ups for two years?

Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part in this study, you'll be taking Risdiplam (Evrysdi) as a liquid medicine. The study will last for a total of two years, during which time you'll have regular visits to the clinic. These visits will involve various tests to see how you're doing, such as checking your muscle strength, movement, and overall physical abilities. You might also have blood tests to look at certain markers. All these assessments help the doctors understand how the medicine is working and ensure your safety. The research team will explain everything in detail, including how often you'll need to come in and what each visit will involve.

Potentiella risker och fördelar

Taking part in any study has potential benefits and risks. A potential benefit of this study is that Risdiplam might improve your daily life and physical abilities. It also contributes valuable information that could help others with SMA in the future. However, like all medicines, Risdiplam can have side effects, and some might be serious. The study team will monitor you closely for any unwanted effects. You'll always have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Platser (1)

Vissa platsangivelser är ungefärliga. Vi arbetar på att förbättra detta — vänligen kontrollera med testteamet innan du reser.

—
Obekräftad
Belgien

Vanliga frågor

What condition is this study for?

This study is for adults with Spinal Muscular Atrophy (SMA) type 2 or 3, or those with up to 4 copies of the SMN2 gene.

What is the medicine being tested called?

The medicine being tested is called Risdiplam, also known as Evrysdi.

How long will the study last if I take part?

If you take part, the study will last for a total of two years.

What will doctors be looking for in this study?

Doctors will be looking to see if Risdiplam improves your daily life and physical abilities, and checking its safety.

Kan jag sluta delta i studien om jag ändrar mig?

Ja, du kan välja att lämna studien när som helst, av vilken anledning som helst, utan att det påverkar din medicinska vård.

Hur du får reda på mer

Officiell rättegångsprotokoll

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "Longitudinal study of clinical outcome measures in adult pat…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Fullständigt namn *E-post *Telefon (valfritt) Postnummer (valfritt)

Är det något du vill att forskarteamet ska veta? (valfritt) Jag godkänner att Patient.info kan dela mina uppgifter med forskarteamet för denna studie så att de kan kontakta mig om att delta. Jag förstår att mina uppgifter kommer att lagras säkert, endast användas för detta ändamål, raderas inom 12 månader om jag inte anmäler mig, och att jag kan dra mig ur när som helst genom att skicka ett e-postmeddelande research@patient.info. Se vår integritetspolicy för detaljer. (Laglig grund: samtycke, UK GDPR Art. 6(1)(a) & Art. 9(2)(a).)

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.